Entropy Technologies LP Has $826,000 Stock Position in Progyny, Inc. (NASDAQ:PGNY)

Entropy Technologies LP raised its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 5.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 47,883 shares of the company’s stock after purchasing an additional 2,499 shares during the quarter. Entropy Technologies LP owned approximately 0.06% of Progyny worth $826,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Leibman Financial Services Inc. boosted its stake in shares of Progyny by 100.7% in the 4th quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company’s stock valued at $1,096,000 after purchasing an additional 31,872 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in Progyny by 90.1% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after acquiring an additional 695,740 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its holdings in Progyny by 15.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 976,501 shares of the company’s stock worth $16,366,000 after acquiring an additional 132,672 shares during the period. Aurora Investment Counsel bought a new position in shares of Progyny in the 3rd quarter worth about $1,280,000. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of Progyny in the 4th quarter valued at about $989,000. Institutional investors own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on PGNY. JPMorgan Chase & Co. raised their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Canaccord Genuity Group reduced their price objective on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, November 13th. Bank of America lifted their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday. Barclays cut their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $19.00 price target (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Progyny currently has an average rating of “Hold” and an average target price of $25.83.

Insider Buying and Selling at Progyny

In other news, CEO Peter Anevski bought 209,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the transaction, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman David J. Schlanger bought 150,000 shares of Progyny stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the acquisition, the chairman now owns 228,269 shares of the company’s stock, valued at $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company’s stock.

Progyny Stock Performance

Shares of NASDAQ PGNY opened at $22.39 on Wednesday. The firm’s 50-day simple moving average is $18.62 and its 200 day simple moving average is $18.81. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of 38.60, a PEG ratio of 2.18 and a beta of 1.34. Progyny, Inc. has a fifty-two week low of $13.39 and a fifty-two week high of $42.08.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.26). The company had revenue of $286.63 million for the quarter, compared to analysts’ expectations of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.16 EPS. On average, sell-side analysts predict that Progyny, Inc. will post 0.6 EPS for the current year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.